How should Ryzodeg (insulin degludec‑aspart) be started using a two‑thirds morning and one‑third evening dosing schedule, and can empagliflozin and linagliptin be given together?

Starting Ryzodeg and Combining with Empagliflozin + Linagliptin

When initiating Ryzodeg (insulin degludec/aspart), start with 10 units once daily with your largest meal, then titrate by 2 units every 3 days based on fasting glucose targets—the 2/3 morning and 1/3 evening split dosing applies to traditional premixed insulins like NPH combinations, not to Ryzodeg. Yes, empagliflozin and linagliptin can be safely co-administered together with Ryzodeg without dose adjustments 1, 2.

Understanding Ryzodeg Dosing

The confusion here stems from mixing traditional premixed insulin dosing strategies with modern co-formulations. The 2/3 morning and 1/3 evening split you're referencing is the old approach for NPH-based premixed insulins (like 70/30), where total daily dose is divided with roughly 2/3 before breakfast and 1/3 before dinner 3.

Ryzodeg works differently and should NOT be dosed this way. Here's the correct approach:

Initial Dosing of Ryzodeg

• Start: 10 units once daily with your largest or most carbohydrate-rich meal 4
• Titration: Increase by 2 units every 3 days (or weekly in 2-unit steps) to reach fasting plasma glucose targets 4
• Target: Individualized fasting glucose goals (typically 80-130 mg/dL for most patients)

Intensification to Twice-Daily Ryzodeg

When once-daily dosing fails to achieve HbA1c targets despite adequate fasting glucose control:

• Add a second injection with another main meal
• Dose distribution varies by prior insulin type 5:
  • If switching from low-ratio premixed insulin (like 70/30): Expect to use approximately 20% less total insulin degludec component at 6 months
  • If switching from mid-ratio premixed insulin (like 50/50): May need approximately 30% more total insulin degludec component at 6 months

Combining Empagliflozin + Linagliptin with Ryzodeg

Yes, this triple combination is safe and effective 1, 2, 6, 7.

Key Evidence Supporting Combination:

• Pharmacokinetic compatibility confirmed: Empagliflozin and linagliptin show no clinically meaningful drug interactions when co-administered 2
• Complementary mechanisms: SGLT2 inhibition (empagliflozin) + DPP-4 inhibition (linagliptin) + insulin provide additive glycemic benefits through different pathways 8, 9
• Real-world data: The combination of empagliflozin/linagliptin (25/5 mg) added to insulin therapy reduced HbA1c by 1.1%, FPG by 47 mg/dL, and body weight by 2.64 kg over 12 weeks 6

Practical Considerations When Combining:

Insulin dose adjustments needed:

• Reduce Ryzodeg dose by 10-20% when adding empagliflozin to prevent hypoglycemia 3
• Empagliflozin provides additional glucose-lowering through urinary glucose excretion, reducing insulin requirements
• Monitor closely for first 2-4 weeks after adding SGLT2 inhibitor

Advantages of this combination:

• Cardiovascular benefits: Empagliflozin reduces CV death (HR 0.62) and heart failure hospitalization 1
• Weight reduction: Empagliflozin causes 2-3 kg weight loss, offsetting insulin-associated weight gain 7
• Blood pressure reduction: Systolic BP drops 7-8 mmHg with empagliflozin 6, 7
• Low hypoglycemia risk: Linagliptin is glucose-dependent and doesn't increase hypoglycemia 10, 9

Safety Monitoring:

Watch for:

• Genital mycotic infections: Occurs in ~8-9% with empagliflozin 6
• Volume depletion: Especially in elderly or those on diuretics
• DKA risk: Rare but possible with SGLT2 inhibitors, even with normal glucose
• Hypoglycemia: More likely in first weeks after adding medications

Contraindications to consider:

• Avoid empagliflozin if eGFR <30 mL/min/1.73m²
• Use caution with recurrent UTIs or genital infections

Clinical Algorithm

1. Start Ryzodeg: 10 units once daily with largest meal
2. Titrate: Increase 2 units every 3 days until fasting glucose at target
3. Add empagliflozin/linagliptin: Use 25/5 mg fixed combination once daily
4. Reduce Ryzodeg: Decrease by 10-20% when adding empagliflozin
5. Monitor: Check glucose daily for 2 weeks, then adjust
6. Intensify if needed: Add second Ryzodeg injection if HbA1c remains >7% after 3 months

Common pitfall: Don't apply the old 2/3 morning and 1/3 evening NPH dosing strategy to Ryzodeg—this modern co-formulation has a different pharmacokinetic profile with ultra-long basal coverage (degludec) plus rapid-acting component (aspart) that doesn't require this traditional split 11, 4.